- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01507506
Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma (SPECTRO GLIO)
Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging
This is a multi-institutional phase III clinical study of interventional type. The trial will include 220 patients with confirmed unifocal glioblastoma over a period of 3 years + 3 years of follow up.
Patients with unifocal glioblastoma (diagnosis confirmed by histology on tumoral biopsy or surgical specimen) and who meet all eligibility criteria will be randomized in one chemoradiotherapy arm :
- Conventional arm: 3-dimensional conformational radiotherapy + Temozolomide
- Experimental arm : simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide The patient monitoring will be regular and standardized. The main objective of this study is to improve overall survival of patients treated in experimental group (with simultaneous integrated boost).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Albi, France, 81000
- Clinique Claude Bernard
-
Clermont-ferrand, France, 63011
- Centre Jean Perrin
-
Dijon, France, 21000
- Centre Georges François Leclerc
-
Lyon, France, 69373
- Centre LEON BERARD
-
Lyon, France, 69002
- Hospices Civils de Lyon (Hôpital Lyon Sud/Hôpital P. Wertheimer)
-
Marseille, France, 13385
- AP HM - Hôpital La Timone
-
Montpellier, France, 34298
- Centre Val D'Aurelle
-
Saint-Priest-En-Jarez, France, 42271
- Institut de Cancérologie Lucien Neuwirth
-
Strasbourg, France, 67065
- Centre Paul Strauss
-
Strasbourg, France, 67065
- CHU de Strasbourg
-
Toulouse, France, 31052
- Institut Claudius Regaud
-
Valence, France, 26953
- Centre Marie Curie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have unifocal glioblastoma (grade IV astrocytoma, WHO classification). The GBM can be:
- Or resectable and the patient has received curative surgery
- Or unresectable, and the largest tumor diameter (contrast enhancement) must be less than 5 cm on MRI
- In all cases, the diagnosis must be confirmed by a pathologist. In patients for whom surgery is not possible, the diagnosis is confirmed by a biopsy of tumor tissue.
- Methylation status of MGMT gene promoter is known
- Patients who have undergone resection should have received an MRI or a scan after surgery in order to visualize residual tumor. If not, the operative report must be available.
- Surgery or biopsy must have occurred 45 days before the start of radiotherapy.
- WHO ≤ 2
- Age ≥ 18 years
- Signed Consent collected before any specific procedure in the study
- Patient member in a national insurance scheme
Exclusion Criteria:
- Signs of hemorrhage on pre-radiotherapy MRI preventing a good spectrometric analysis
- Patient with multifocal glioblastoma
- Tumor located within 2 cm of the optic chiasm
- Patient with leptomeningeal metastases,
- patients prone to epileptic seizures despite treatment with anticonvulsant
- Patients who received other previous treatment for glioblastoma multiforme
Abnormal haematological results at inclusion with:
- Neutrophils < 1500/mm3
- Blood-platelets < 100000/mm3
- Severe or chronic renal insufficiency (creatinin clearance ≤ 30 ml/min calculated using Cockroft-Gault's formula
- Patient unable to follow procedures, visits, examinations described in the study
- Any usual formal indication against imaging examinations (important claustrophobia, pace maker ...)
- Pregnant women or nursing mothers can not participate in the study. Women of childbearing age must have a negative pregnancy test within 72 hours prior to study entry
- Men and women of childbearing age must use effective contraception at study entry and throughout the study
- Any concomitant or previous malignant disease within 5 years prior to study entry
- Any prior systemic chemotherapy within 5 years prior to inclusion (for malignant disease in medical history)
- Any other medical conditions making the inclusion of the patient in the study inappropriate in the opinion of the investigator
- Patient under legal guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Conventional arm
3-dimensional conformal radiotherapy + Temozolomide
|
Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging. + Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
|
Experimental: Experimental arm
simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
|
Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed + Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival defined as the time from randomization to the date of death or date of last follow-up news (censured data)
Time Frame: 8 years
|
8 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival, defined as the time from randomization to the date of progression or death
Time Frame: 8 years
|
8 years
|
Safety evaluated according to the classification of NCI CTCAE (Common Terminology Criteria for Adverse Events)V3.0
Time Frame: 8 years
|
8 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, Catalaa I, Boetto S, Khalifa J, Attal J, Peyraga G, Gomez-Roca C, Uro-Coste E, Noel G, Truc G, Sunyach MP, Magne N, Charissoux M, Supiot S, Bernier V, Mounier M, Poublanc M, Fabre A, Delord JP, Cohen-Jonathan Moyal E. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. BMC Cancer. 2019 Feb 21;19(1):167. doi: 10.1186/s12885-019-5317-x.
- Ken S, Deviers A, Filleron T, Catalaa I, Lotterie JA, Khalifa J, Lubrano V, Berry I, Peran P, Celsis P, Moyal EC, Laprie A. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination. J Neurooncol. 2015 Sep;124(3):465-73. doi: 10.1007/s11060-015-1860-8. Epub 2015 Jul 19.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08 TETE 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University Hospital OstravaRecruiting
-
UNICANCERNational Cancer Institute, FranceRecruitingBreast Cancer | DCIS | Low Risk DCIS | Breast Conserving Surgery | Radiotherapy OmissionFrance
-
University Medical Center GroningenCatharina Ziekenhuis Eindhoven; Academisch Medisch Centrum - Universiteit van... and other collaboratorsActive, not recruiting
-
Fudan UniversityZhejiang Cancer Hospital; Huashan Hospital; Henan Cancer Hospital; Hunan Cancer... and other collaboratorsNot yet recruiting
-
The Netherlands Cancer InstituteLeiden University Medical CenterRecruitingSoft Tissue SarcomasNetherlands
-
Radboud University Medical CenterKoningin Wilhelmina Fonds; Maastro Clinic, The NetherlandsTerminatedSpinal MetastasesNetherlands
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownGastric CancerSingapore
-
IRCCS San RaffaeleRecruitingGynecologic Cancer | Radiotherapy Side Effect | Survivorship | Radiotherapy; Complications | Progression, Disease | Progression, ClinicalItaly